Literature DB >> 29731020

The Genetic Link Between Diabetes and Atherosclerosis.

Stephanie Ross1, Hertzel Gerstein2, Guillaume Paré3.   

Abstract

Epidemiological studies have indicated that the risk of atherothrombotic coronary artery disease (CAD) is higher in patients with diabetes, but these results have not been consistently observed across clinical trials. To address this apparent discrepancy, we can apply the results of genome-wide association studies (GWAS) to provide a better understanding of the shared genetic architecture of diabetes and atherothrombotic CAD. For instance, a large GWAS has identified 16 novel loci that are associated with both diabetes and atherothrombotic CAD. These genetic variants may also be used to assess potential causal relationships reported in observational studies and clinical trials through Mendelian randomization analyses. For example, several Mendelian randomization analyses have shown that diabetes is associated with CAD independent of other risk factors (odds ratio [OR]: 1.63, 95% confidence interval [CI]: 1.23-2.07; P = 0.002). Furthermore, Mendelian randomization analyses can provide more insight into the perceived risk of diabetes among patients without diabetes receiving statin therapy. Here, genetically lower activity of HMG-CoA reductase (HMGCR) was associated with a modest increase in diabetes (OR per allele: 1.02, 95% CI: 1.00-1.05). These results highlight the biological mechanisms that link diabetes with the use of statins. In addition, this work illustrates the great potential value of genetic studies to clarify the mechanistic relationships among atherosclerotic vascular disease, dysglycemia, and diabetes. More research is needed to delineate and subsequently better understand the genetic links between diabetes and atherosclerosis.
Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29731020     DOI: 10.1016/j.cjca.2018.01.016

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  Network analysis of atherosclerotic genes elucidates druggable targets.

Authors:  Sheuli Kangsa Banik; Somorita Baishya; Anupam Das Talukdar; Manabendra Dutta Choudhury
Journal:  BMC Med Genomics       Date:  2022-03-03       Impact factor: 3.063

2.  C1q tumor necrosis factor-related protein 4 is associated with coronary artery disease in patients with type 2 diabetes.

Authors:  Jie Gao; Jun Lu; Junhui Qiu; Dusang Sun; Bilin Xu; Zhihua Wang; Tao Lei
Journal:  J Diabetes Investig       Date:  2022-06-22       Impact factor: 3.681

Review 3.  An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease.

Authors:  Nicholas P Iskandar; Akshay J Reddy; Allen Dang; Muhammad S Ghauri; Mildred Min; Mark Bachir; Alex Bachir; Himanshu Wagh; Nathaniel Tak; Hetal Brahmbhatt
Journal:  Cureus       Date:  2022-08-25

4.  Human in vitro vascularized micro-organ and micro-tumor models are reproducible organ-on-a-chip platforms for studies of anticancer drugs.

Authors:  Yizhong Liu; Courtney Sakolish; Zunwei Chen; Duc T T Phan; R Hugh F Bender; Christopher C W Hughes; Ivan Rusyn
Journal:  Toxicology       Date:  2020-09-24       Impact factor: 4.221

Review 5.  New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis.

Authors:  Ting Yuan; Ting Yang; Huan Chen; Danli Fu; Yangyang Hu; Jing Wang; Qing Yuan; Hong Yu; Wenfeng Xu; Xiang Xie
Journal:  Redox Biol       Date:  2018-10-19       Impact factor: 11.799

Review 6.  Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk.

Authors:  Vadim V Genkel; Igor I Shaposhnik
Journal:  Int J Chronic Dis       Date:  2020-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.